Acasti Pharma Inc. (ACST)
NASDAQ: ACST · IEX Real-Time Price · USD
2.89
-0.02 (-0.69%)
At close: Dec 29, 2023, 4:00 PM
2.85
-0.04 (-1.38%)
After-hours: Dec 29, 2023, 6:28 PM EST
Acasti Pharma Market Cap
Acasti Pharma has a market cap or net worth of $27.16 million as of December 29, 2023. Its market cap has increased by 24.04% in one year.
Market Cap
27.16M
Enterprise Value
6.82M
1-Year Change
24.04%
Ranking
Category
Stock Price
$2.89
Market Cap Chart
Since February 14, 2012, Acasti Pharma's market cap has decreased from $3.44B to $27.16M, a decrease of -99.21%. That is a compound annual growth rate of -33.47%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Dec 29, 2023 | 27.20M | -0.73% |
Dec 28, 2023 | 27.40M | -4.53% |
Dec 27, 2023 | 28.70M | 36.02% |
Dec 26, 2023 | 21.10M | -1.86% |
Dec 22, 2023 | 21.50M | 1.90% |
Dec 21, 2023 | 21.10M | - |
Dec 20, 2023 | 21.10M | 4.98% |
Dec 19, 2023 | 20.10M | 0.50% |
Dec 18, 2023 | 20.00M | -0.99% |
Dec 15, 2023 | 20.20M | 1.00% |
Dec 14, 2023 | 20.00M | 0.50% |
Dec 13, 2023 | 19.90M | -1.97% |
Dec 12, 2023 | 20.30M | -2.40% |
Dec 11, 2023 | 20.80M | -3.70% |
Dec 8, 2023 | 21.60M | -1.37% |
Dec 7, 2023 | 21.90M | 4.29% |
Dec 6, 2023 | 21.00M | -1.87% |
Dec 5, 2023 | 21.40M | -2.28% |
Dec 4, 2023 | 21.90M | 7.88% |
Dec 1, 2023 | 20.30M | -0.49% |
Nov 30, 2023 | 20.40M | 5.70% |
Nov 29, 2023 | 19.30M | -1.53% |
Nov 28, 2023 | 19.60M | -3.45% |
Nov 27, 2023 | 20.30M | 2.01% |
Nov 24, 2023 | 19.90M | 1.53% |
View and export this data all the way back to 2012.
Start Free Trial.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Forte Biosciences | 29.86M |
Senti Biosciences | 29.40M |
Elutia | 28.19M |
Freeline Therapeutics Holdings | 27.76M |
Qilian International Holding Group | 27.58M |
PHAXIAM Therapeutics | 26.97M |
Coeptis Therapeutics | 26.74M |
Corbus Pharmaceuticals Holdings | 26.72M |